Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31, and risk of subsequent HPV infection: results from a populationbased study in Costa Rica. - Viscidi, R P; Schiffman, M; Hildesheim, A (Cancer Epidemiol Biomarkers Prev, 2004)
et al